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Abstract
Background: In HIV infected patients, the impact of ribavirin (RBV) pharmacology on sustained virologic response
(SVR) to hepatitis C virus (HCV) treatment has not been fully investigated. The objective of this study was to compare the
early RBV plasma exposure between a population of HIV-HCV coinfected patients and an HCV monoinfected group.
Methods: Early RBV plasma exposure (expressed as Area Under the Curve (AUC) from 0 to 4 h) after a 600 mg first dose
of RBV was measured in a population of HIV-HCV coinfected patients in comparison with an HCV monoinfected group.
Peripheral blood samples were collected before the 600 mg RBV first dose (T0) to ensure no detectable baseline plasma
RBV, and then 30 mn, 1, 2 and 4 hours after RBV intake (T0.5, T1, T2 and T4).
Results: Eighty-six patients with chronic hepatitis C entered the study among whom 23 (27%) were HIV-HCV
coinfected. Coinfected patients had a significantly lower RBV-AUC 0-4h (median: 1469 μg*h/L [range 936–3677])
compared with monoinfected patients (2030 μg*h/L [851–7700]; p = 0.018). This RBV under exposure in coinfected
patients persisted after normalization of AUC to RBV dose per kilogram of body weight (182 μg*h/L [110–425] versus
271 μg*h/L [82–1091], p = 0.001).
Conclusions: These results suggest that lower early bioavailability of RBV could be one of the reasons for lower SVR in
HIV-HCV coinfected patients treated with pegylated interferon/RBV combination therapy. RBV plasma underexposure
seems to be associated with the immunological status of the patients with lower AUC0-4h values observed in the more
immunosuppressed coinfected patients.
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Background
Worldwide prevalence of hepatitis C virus (HCV) infec-
tion in human immunodeficiency virus (HIV) infected
patients is about 33%[1-3] and this pathology represents
one of the main comorbidities in this population [4,5].
Before the use of protease inhibitors for genotype 1
HCV infection, combination of ribavirin (RBV) and
pegylated interferon-α (PEG-IFN) was the standard of
care for treatment of chronic HCV patients and it is still
the standard for non-1 genotype infection with or with-
out HIV coinfection. All guidelines to adjust RBV doses
have been defined in monoinfected patients but are also
used in HIV-HCV ones. According to these guidelines
and excepted for genotype 2 or 3 infected patients, RBV
doses must be adapted to body weight [6]. Studies have
shown that high RBV plasma concentrations could im-
prove early virological response rates [7,8]. However,
RBV daily dose, even adjusted for body weight is poorly
correlated with RBV plasma concentration [9,10] due to
a large inter-individual variability in exposure [11-13].
Different explanations have been proposed for this
variability: i) the lean body weight would be a better
covariate with a linear influence on RBV clearance
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[14]; ii) RBV exposure depends on creatinine clearance
[15]; iii) the RBV pharmacokinetics could be impacted
by the pharmacological or pathological context of
HIV-HCV coinfection [16]. Loustaud-Ratti et al., showed
that RBV plasma exposure after a single dose of 600 mg in
HCV monoinfected patients was predictive of sustained
virological response (SVR) and proposed a threshold of
1755 μg.h/L for the RBV plasma AUC from 0 to 4 h post-
dose to discriminate patients with subsequent SVR from
those with non-response [17]. This is currently the only
data that can be used to interpret early RBV exposure and
determine the optimal dose to initiate treatment. The
impact of the pharmacokinetic properties of RBV in
HIV patients has not been fully investigated. As for
HCV monoinfected patients, we know that a large
inter-individual variability in RBV plasma concentrations
exists in HIV-HCV coinfected patients and that RBV ex-
posure is associated with both efficacy and anemia [8].
Moreover, the SVR rate is known to be lower in HIV-
HCV coinfected than in HCV monoinfected patients. One
possible explanation could be that, as for other drugs,
HIV infected patients present a lower bioavailability of
RBV [18]. The aim of this study was to determine early
plasma exposure evaluated by the AUC0-4h after a first
dose of RBV in a population of HIV-HCV coinfected
patients and to compare the results to those obtained
in HCV monoinfected patients.
Methods
Patients
Consecutive patients seen by six physicians during a
12 months period for a chronic hepatitis C infection
(Edouard Herriot and Croix-Rousse hospitals, Lyon,
France) and initiating a PEG-IFN/RBV therapy between
February 2009 and February 2010 entered the study.
RBV was taken with light breakfast or snack. Plasma
AUC determination after a first dose of RBV (600 mg)
was obtained before therapy initiation as described by
Loustaud-Ratti et al. [17] to evaluate RBV bioavailability.
Treatment was then initiated using a weight-based RBV
dose after possible adaptation following the AUC results.
Patients with low ribavirin exposure (as assessed by
AUC result) were usually treated with a 200 mg higher
ribavirin dose. Patients were divided into two groups
according to their HIV status. To be included, patients
had to have detectable HCV RNA, and for HIV-HCV
coinfected patients to be on combined antiretroviral
therapy (cART) for at least one month prior to RBV
initiation. Patients with RBV treatment within the past
three months were excluded. All patients gave their in-
formed consent before they entered the study. Following
characteristics were recorded at baseline (day of the first
RBV dose intake): age, body weight, body mass index
(BMI), creatinine level, glomerular filtration rate (GFR,
estimated by Cockroft clearance and Modification of the
Diet in Renal Disease (MDRD) formula), hemoglobin,
aminotransferases, fibrosis stage, HCV genotype, HCV-
and HIV RNA quantification, CD4 level and antiretro-
viral drugs.
Methods
The plasma AUC was determined for each patient before
the antiviral treatment or at the first day. Patients re-
ceived a single RBV dose of 600 mg (T0) and peripheral
blood samples were collected before the administration
to ensure undetectable baseline plasma RBV, and then
30 mn, 1, 2 and 4 hours after RBV intake (T0.5, T1, T2
and T4). To avoid RBV exchange between plasma and
red blood cells, samples were placed in ice immediately
after withdrawal and centrifuged as soon as possible
(maximum lag time was 1 h). RBV plasma concentrations
were measured using a validated High-Performance
Liquid Chromatography-Diode Array Detector method
[19]. This method is highly specific, sensible (limit of
quantification = 0.05 mg/L), and precise (total imprecision,
calculated by measuring the coefficient of variation (CV)
of the internal quality control values was less than 10% for
concentrations from 0.20 to 5.00 mg/L).
Pharmacokinetic analysis
RBV AUC was calculated using the Table Curve 2D soft-
ware (Systat Software Inc). As a large variability of body
weight (BW) was observed and that all patients received
the same RBV first dose, AUC were also normalized as
AUC0-4h/dose (in mg/BW in kg). Results of AUC and
normalized AUC were analyzed according to the two
groups defined by the HIV status.
Statistical analysis
All quantitative variables were expressed as median and
range. Comparisons of data were made using the non-
parametric Mann–Whitney test. Statistical analysis was
performed using the Statistica® software package (StatSoft
Inc). A multivariate logistic regression analysis was
conducted to identify factors potentially associated with
RBV underexposure (defined by an AUC <1755 μg.h/L).
Variables significantly associated with RBV underexpos-
ure in univariate analysis and variables suspected to be
associated with it, were included in the multivariate
model. A p value below 0.05 was considered as statisti-
cally significant.
Ethical considerations
RBV pharmacokinetics monitoring is routinely performed
in our unit for patients treated with PEG-IFN/RBV. This
monitoring includes measurement of RBV AUC before
therapy initiation and assessment of RBV plasma concen-
tration during treatment. RBV monitoring is used to adapt
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RBV dose and to manage anemia. According to the French
legislation (Public Health Code modified by the law no.
2004–806, 9 August 2004 and the Huriet–Sérusclat act
88–1138, 20 December 1988) and since this study was
observational, no ethics committee approval was necessary.
Results
Eighty-six Caucasian patients with chronic hepatitis C
entered the study. Among them, 62 were males (72%)
and 23 (27%) were HIV-HCV coinfected. Most of them
(85%) were infected with HCV genotype 1 or 4. Baseline
characteristics are presented in Table 1.
Among HIV-HCV coinfected patients, 20/23 (87%)
had a negative HIV RNA viral load at baseline (<50 cop-
ies/mL) and 57% had a CD4 count above 500 cells/mm3.
Most of them received two nucleoside reverse transcript-
ase inhibitors (NRTIs) (22 patients): tenofovir and emtri-
citabine for 20 of them (91%) and didanosine associated
with stavudine or tenofovir for two. One patient received
a cART regimen without NRTI. No patient received
abacavir. Nucleoside treatment was associated with a
protease inhibitor in 14 patients: seven patients received
lopinavir, four darunavir, two atazanavir and one saquin-
avir. All these patients were also treated with ritonavir as
a booster. Eight patients received a non-nucleoside re-
verse transcriptase inhibitor (NNRTI): four nevirapine,
three efavirenz and one etravirine.
Finally, four patients received raltegravir, associated
with a protease inhibitor regimen in three of them and
with tenofovir and emtricitabine in one. One patient re-
ceived maraviroc in association with a protease inhibitor,
NNRTI and raltegravir.
Medians of AUC0-4h and AUC0-4h normalized to the
first RBV dose expressed in mg/kg BW were 1469 μg.h/L
and 182 (μg.h/L)/(mg/kg) respectively. According to the
threshold of 1755 μg.h/L defined in HCV monoinfected
patients, 14/23 (61%) coinfected patients were found
to have an AUC0-4h below this value. No significant
Table 1 Main baseline characteristics of HCV monoinfected and HIV-HCV coinfected patients (n = 86)
Characteristics HCV (n = 63) HIV-HCV (n = 23) p value
Gender ratio (M/F) 2.0 6.7 0.063
Age (years) 50 (23–74) 46 (35–60) 0.066
Body weight (kg) 75 (41–130) 69 (52–96) 0.032
Men body weight (kg) 79 (44–130) 69 (52–96) 0.008
Body mass index (BMI) 25.7 (16.4-43.3) 22.1 (17.6-32.8) 0.003
Men body mass index (BMI) 25.8 (18.4-43.3) 22.2 (17.6-32.8) 0.002
Creatinine (μmol/L) 76 (49–189) 82 (45–123) 0.164
Cockroft clearance (mL/min) 105.7 (44–257.7) 90.2 (67.2-202.9) 0.244
MDRD (mL/min) 90.9 (34.2-167.5) 89.5 (58.2-144.7) 0.880
ALT (IU/mL) 62 (20–383) 60.5 (20–1492) 0.853
AST (IU/mL) 47 (20–402) 57 (26–969) 0.485
HCV RNA (log IU/mL) 6.1 (3.59-6.99) 6.4 (2.81-7.39) 0.111
Hemoglobin level (g/dl) 14.5 (8.2-17.2) 15.2 (12.1-18.8) 0.036
Men hemoglobin level (g/dl) 15 (8.3-17.2) 15.2 (12.1-18.8) 0.239
HCV genotype n (%) 0.566
1 48 (76) 14 (61)
2 2 (3) 1 (4)
3 6 (10) 4 (17)
4 7 (11) 4 (17)
Fibrosis score (Metavir) n (%) 0.780
0 – 2 29 (46) 12 (52)
3 – 4 34 (54) 11 (48)
HCV treatment status at baseline n (%) 0.434
HCV treatment naive 19 (30) 9 (41)
Nonresponders 25 (40) 9 (41)
Relapsers 19 (30) 4 (18)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; MDRD, Modification of the Diet in Renal Disease. Bold style indicates statistical significance.
Quantitative variables are expressed as median and range.
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difference was found for cART type and duration, HIV
viral load and CD4 level between the 2 sub-groups of
HIV-HCV coinfected patients defined by this threshold
(Table 2). All three patients found to have a detectable
HIV RNA, had an AUC0-4h below 1755 μg.h/L. With re-
gard to the immune status, 61% of patients had a CD4
level below the retained cutoff of 500/mm3. Interestingly,
the AUC0-4h was significantly lower for these patients than
for those with CD4 level greater than 500/mm3 with
values of 1270 μg.h/L and 1840 μg.h/L respectively (p =
0.047). For these 2 sub-groups of coinfected patients, nor-
malized AUC were 144 and 195 (μg.h/L)/(mg/kg) but the
difference did not reach statistical significance. Table 3
summarizes these results.
For the reference group of HCV monoinfected pa-
tients, median AUC0-4h and normalized AUC0-4h were
2030 μg.h/L and 271 μg.h/L respectively. In comparison
to HIV-HCV coinfected patients, these two parameters
were significantly higher (p = 0.018 and 0.001, respec-
tively). Sixty-eight percent of monoinfected patients had
an AUC0-4h above the threshold of 1755 μg.h/L vs 39%
of HIV-HCV coinfected patients (p = 0.014). The median
AUC0-4h was slightly higher in naive HCV patients than
in relapsers and non-responders (2434 μg.h/L, 2025 μg.
h/L and 1873 μg.h/L, respectively, although this diffe-
rence did not reach statistical significance (p = 0.165).
Different factors potentially associated with RBV pharma-
cokinetics variability were investigated. Except for body
weight, BMI, and hemoglobin level, baseline characteristics
did not differ between monoinfected and coinfected pa-
tients. Median body weight and BMI were lower in coin-
fected patients than in monoinfected ones (69 kg vs 75 kg ,
p = 0.032 and 22.1 vs 25.7, p = 0.003, respectively). Con-
versely, hemoglobin level was lower in monoinfected pa-
tients (median 14.5 g/dl) than in coinfected patients
(15.2 g/dl; p = 0.036).
Multivariate logistic regression analysis indicated that
presence of HIV coinfection (OR = 3.76, 95% CI [1.21-11.6];
p = 0.022) and male gender (OR = 4.59, 95% CI [1.15-18.3];
p = 0.031) were independently associated with RBV under-
exposure (Table 4).
Discussion
Using the AUC0-4h method, our results clearly showed a
plasma underexposure in HIV-HCV coinfected patients
after a single dose intake of RBV in comparison with
monoinfected patients. The pharmacokinetics of RBV is
less documented in HIV-HCV coinfected patients than
in monoinfected ones but some studies showed that the
achievement of RBV cutoffs was a predictive factor of
SVR independent of HIV coinfection [20,21]. The het-
erogeneity of our cohort of HIV-HCV coinfected pa-
tients was representative of a treated HIV population in
a hospital environment (57% with CD4 > 500 cells/mm3;
87% with undetectable HIV viral load under HAART;
patients mainly under 2 NRTIs + 1 boosted protease
inhibitor) [22]. The choice of AUC0-4h was made in
accordance with the study of Loustaud-Ratti et al. for
HCV monoinfected patients [17]. Indeed, the authors
showed that the abbreviated AUC0-4h was highly corre-
lated to the full AUC0-12h because it described the main
inter-individual variability of RBV pharmacokinetic pa-
rameters (i.e. absorption and distribution phases). Inter-
estingly in our study, more than 60% of coinfected
patients had an AUC0-4h below the threshold of 1755 μg.
h/L defined as associated with SVR in HCV monoin-
fected patients [17]. In comparison, only 32% of mono-
infected patients of our study had an AUC0-4h below this
value. Demographic or biological parameters were col-
lected in order to detect confounding factors that could
affect differences in early RBV exposure between both
populations. Some differences were found. The first of
Table 2 Particular characteristics of HIV-HCV coinfected patients according to RBV AUC0-4h threshold (n = 23)
All (n = 23) RBV AUC 0-4h <1755 μg.h/L
(n = 14)
RBV AUC 0-4h >1755 μg.h/L
(n = 9)
p value
HIV RNA <50 copies/mL, n (%) 20 (87) 11 (79) 9 (100) 0.253
HIV RNA copies/mL 50 (20–9850) 50 (20–9850) 50 (40–50) 0.687
CD4 (cells/mm3) 543 (325–1067) 498 (325–993) 543 (368–1067) 0.614
CD4% 30 (10–48) 29.5 (10–48) 32 (27–45) 0.174
Duration of HIV treatment (years) 11 (1–19) 11 (1–16) 10 (2–19) 0.825
Antiretroviral therapy, n (%)
Protease inhibitor 14 (61) 7 (50) 7 (78)
Nucleoside reverse transcriptase inhibitor (NRTI) 21 (91) 13 (93) 8 (89)
Non-nucleoside reverse transcriptase inhibitor (NNRTI) 8 (35) 6 (43) 2 (22)
Integrase inhibitor 4 (17) 1 (<1) 3 (33)
Receptor CCR5 inhibitor 1 (<1) 0 1 (11)
Quantitative variables are expressed as median and range.
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them was a body weight significantly lower for coinfected
patients. As the initial RBV dose was the same (600 mg)
for all patients, irrespectively of this parameter, early ex-
posure was normalized for RBV dose expressed as mg/kg
BW. Normalized AUC0-4h remained significantly different
between both groups. In addition, hemoglobin level was
higher in coinfected than in monoinfected patients. It is
well known that RBV is highly concentrated in red blood
cells [23], but this parameter was not expected to in-
fluence AUC0-4h which was determined after a single dose
of RBV. Among other parameters known to have an in-
fluence on RBV exposure is the renal function, but neither
median baseline serum creatinine, nor estimated glome-
rular filtration rate (GFR) calculated by Cockroft-Gault
equation or MDRD formula, differed significantly between
both groups (Table 1). We have determined early RBV ex-
posure regardless of HCV genotype as no difference was
observed in the genotype distribution in each of the two
populations of this study and because we wanted to eva-
luate early bioavailability of RBV independently of the
subsequent treatment response. In the study by Loustaud-
Ratti et al. the population was exclusively constituted of
monoinfected HCV genotype 1 patients. This is the main
difference with our study in which genotypes 1 to 4 were
present but with a majority of genotype 1. Indeed, except
for this parameter and for the distribution of fibrosis
score, baseline characteristics were similar in both studies.
However, 32% of our HCV monoinfected patients had an
AUC0-4h below the 1755 μg.h/L threshold compared with
58% in this historical study. This difference could be ex-
plained by the presence of patients infected by HCV geno-
type 2, 3 or 4 because only two of these 15 patients had an
AUC0-4h below this threshold. Finally, we found a strong
gender ratio in favor of male patients in our coinfected
population. In order to estimate if gender could affect
RBV exposure, we compared parameters which were sta-
tistically different in the whole population. For body
weight the significant difference was even more important
and as expected, this parameter was lower in coinfected
patients (Table 1). Hence the interest of the AUC norma-
lized to the first RBV dose deletes the weight effect. Con-
versely, differences in hemoglobin level were no longer
significant due to the higher proportion of women in the
monoinfected group. In spite of the reduced number of
patients, the difference of AUC0-4h or normalized AUC0-4h
between monoinfected and coinfected male patients was
statistically significant, and the proportion of AUC under
the 1755 μg.h/L threshold remained high. No other differ-
ences in demographic or biological characteristics were
found between the two populations of this study.
Given that there was a strong gender ratio in favor of
male patients and in order to see if gender could affect
Table 3 AUC0-4h and normalized AUC0-4h to RBV 600 mg/body weight
HCV (n = 63) HIV-HCV (n = 23) p value
AUC0-4h (μg.h/L) 2030 (851–7700) 1469 (936–3677) 0.018
Patients with AUC0-4h <1755 (%) 32 61 0.014
Men AUC0-4h (μg.h/L) 1875 (850–7700) 1414 (1034–3677) 0.050
Men with AUC0-4h <1755 (%) 43 65 0.103
Normalized AUC0-4h (μg.h/L)/(mg/kg) 271 (82–1091) 182 (110–425) 0.001
Men normalized AUC0-4h (μg.h/L)/(mg/kg) 266 (82–1091) 173 (110–425) 0.004
CD4 < 500 CD4 ≥ 500
AUC0-4h 1270 (936–2792) 1840 (1280–3677) 0.047
Normalized AUC0-4h 144 (110–425) 195 (154–349) 0.108
Quantitative variables are expressed as median and range. Bold style indicates statistical significance.
Table 4 Univariate and multivariate logistic regression analysis to identify factors potentially associated with ribavirin
underexposure (defined by an AUC < 1755 μg.h/L)
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
HIV coinfection (yes vs no) 3.34 (1.24-9.01) 0.017 3.76 (1.21-11.6) 0.022
Gender (male vs female) 7.00 (1.89-25.9) 0.004 4.59 (1.15-18.3) 0.031
Weight 1.03 (0.99-1.06) 0.067 1.03 (0.99-1.08) 0.142
Age 0.97 (0.93-1.01) 0.160 - -
MDRD 1.00 (0.98-1.02) 0.803 - -
Cockroft 1.01 (0.99-1.02) 0.145 1.00 (0.98-1.02) 0.927
Bold style indicates statistical significance.
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our results, we compared AUC0-4h between monoin-
fected and coinfected male patients. It is noteworthy that
43% of monoinfected and 65% of coinfected male pa-
tients had AUC0-4h below the 1755 μg.h/L threshold,
although this difference did not reach statistical signifi-
cance (p = 0.103). As expected, among HCV monoin-
fected patients, the AUC0-4h was slightly higher in naive
patients than in relapsers and non-responders to a pre-
vious treatment although this difference did not reach
statistical significance probably because of a limited
number of patients in each subgroup.
Unexpectedly, RBV plasma underexposure seems to be
associated with the immunological level of HIV patients.
RBV exposure was indeed better if CD4 cell count was
greater than 500/mm3. In the RIBAVIC study, using PEG-
IFN/RBV therapy in HIV co-infected patients, a trend for
a lower SVR was noted in patients with a CD4 cell count
under 500 versus patients upper this threshold (21% vs
33%, respectively; p = 0.051) [24]. Then, in the PRESCO
trial, a higher dosing of ribavirin (weight-based dosing
with 1000 to 1200 mg) was associated with better SVR
rates but higher risk of anemia [25]. In the present study,
when the immunorestoration under cART was considered
complete, i.e. with a CD4 cell count > 500/mm3, RBV ex-
posure was similar in this HIV sub-group in comparison
with HCV monoinfected population.
Food intake is known to potentially impact RBV bio-
availability. Both the AUCtf (from time zero to the time of
the final quantifiable sample) and Cmax of a single oral
dose of ribavirin were indeed shown to be increased by
co-administration of a high fat meal [26]. However, in the
present study all patients received RBV with light break-
fast or snack which suggests no bias between mono- and
coinfected patients.
Conclusion
In conclusion, HIV-HCV coinfected patients present a
lower RBV exposure which could at least in part explain
the lower response rate of these patients to HCV treat-
ment. This hypothesis should be further investigated on a
larger number of coinfected patients focusing on the im-
mune status of these patients. In the past, recommenda-
tions were to use low dose of RBV in HIV patients in
order to avoid toxicity associated with antiretroviral drugs,
such as zidovudine, stavudine or didanosine [27,28]. How-
ever, these drugs are progressively neglected to the benefit
of less cytotoxic new antiretroviral drugs. So, higher doses
of RBV can be used to improve SVR in coinfected patients,
as suggested in several studies [7,29]. Measurement of
early RBV exposure by determination of AUC0-4h possibly
followed by RBV dose adjustment could help in optimizing
antiviral therapy in HIV-HCV coinfected patients, particu-
larly in the more immunosuppressed ones because RBV
underexposure was noted in this specific sub-group.
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